Did you know:
As noted in the Wall Street Journal, much of the rise in US spending on drugs can be traced to a new class of “specialty” drugs. Indeed, the first nine months of 2012 saw a 22.6% spike in spending for such drugs, many of which are injectible cancer drugs.
The fact is that the new cancer drugs are more expensive than ever. A list of recent approvals inlcudes:
Dendreon’s prostate drug Provenge at $93,000
Pfizer’s targeted lung-cancer treatment Xalkori is $115,000 a year
Bristol-Myers Squibb’s melanoma drug Yervoy is $120,000 per year
Roche’s targeted melanoma med Zelboraf is $56,000 for a 6-month course.
Know what it costs,
ScripTips is a free service provided to physicians and other caregivers by Dr. Paul S. Bradley. Prescription savings drive patient compliance, and Scripta helps make sure your patients are getting “The Best Meds at the Best Price.”